ReviewBMC cancer2019
Portrait of a cancer: mutational signature analyses for cancer diagnostics.
Review in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed.
- Toward identification of common DNA repair process in mutational signatures.bioRxiv : the preprint server for biology · 2026Article
- Cancer-associated mutational patterns reshape miRNA regulatory regions and potentially disrupt miRNA-gene interactions.American journal of clinical and experimental immunology · 2026Article
- Reconstructing the lifelong history of cells and tissues via somatic mutation analysis.Cellular and molecular life sciences : CMLS · 2025Review
- High-throughput characterization of 5886 HER2 variants identifies 112 new in cellulo gain-of-function mutations.Genomics · 2025Article
- Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies.Blood cancer discovery · 2025Article
- Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primary.Nature communications · 2025Article
- New Gain-of-Function Mutations Prioritize Mechanisms of HER2 Activation.medRxiv : the preprint server for health sciences · 2025Article
- Review
- Comprehensive Analysis of Prognostic Alternative Splicing Signatures in Tumor Immune Infiltration in Bladder Cancer.Recent patents on anti-cancer drug discovery · 2025Article
- Using FFPEsig to Remove Formalin-Induced Artifacts and Characterize Mutational Signatures in Cancer.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignancies.bioRxiv : the preprint server for biology · 2024Article
- A comprehensive comparison of tools for fitting mutational signatures.Nature communications · 2024Article
- Somatic mutational landscape across Indian breast cancer cases by whole exome sequencing.Scientific reports · 2024Article
- Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers.The oncologist · 2024Article
- The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review.Virchows Archiv : an international journal of pathology · 2024Review
- Relating mutational signature exposures to clinical data in cancers via signeR 2.0.BMC bioinformatics · 2023Article
- Genetic inhibitors of APOBEC3B-induced mutagenesis.Genome research · 2023Article
- Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2023Article
- Mutational signature dynamics shaping the evolution of oesophageal adenocarcinoma.Nature communications · 2023Article
- Mutational signatures for breast cancer diagnosis using artificial intelligence.Journal of the Egyptian National Cancer Institute · 2023Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundIn the past decade, systematic and comprehensive analyses of cancer genomes have identified cancer driver genes and revealed unprecedented insight into the molecular mechanisms underlying the initiation and progression of cancer. These studies illustrate that although every cancer has a unique genetic make-up, there are only a limited number of mechanisms that shape the mutational landscapes of cancer genomes, as reflected by characteristic computationally-derived mutational signatures. Importantly, the molecular mechanisms underlying specific signatures can now be dissected and coupled to treatment strategies. Systematic characterization of mutational signatures in a cancer patient's genome may thus be a promising new tool for molecular tumor diagnosis and classification.
resultsIn this review, we describe the status of mutational signature analysis in cancer genomes and discuss the opportunities and relevance, as well as future challenges, for further implementation of mutational signatures in clinical tumor diagnostics and therapy guidance.
conclusionsScientific studies have illustrated the potential of mutational signature analysis in cancer research. As such, we believe that the implementation of mutational signature analysis within the diagnostic workflow will improve cancer diagnosis in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.